Titre : Syndrome de Budd-Chiari

Syndrome de Budd-Chiari : Questions médicales fréquentes

Termes MeSH sélectionnés :

MicroRNAs
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Syndrome de Budd-Chiari : Questions médicales les plus fréquentes", "headline": "Syndrome de Budd-Chiari : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Syndrome de Budd-Chiari : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-04-11", "dateModified": "2025-04-06", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Syndrome de Budd-Chiari" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Thrombose veineuse", "url": "https://questionsmedicales.fr/mesh/D020246", "about": { "@type": "MedicalCondition", "name": "Thrombose veineuse", "code": { "@type": "MedicalCode", "code": "D020246", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C14.907.355.830.925" } } }, "about": { "@type": "MedicalCondition", "name": "Syndrome de Budd-Chiari", "alternateName": "Budd-Chiari Syndrome", "code": { "@type": "MedicalCode", "code": "D006502", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "None Shalimar", "url": "https://questionsmedicales.fr/author/None%20Shalimar", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, All India Institute of Medical Sciences, New Delhi, India." } }, { "@type": "Person", "name": "Akash Shukla", "url": "https://questionsmedicales.fr/author/Akash%20Shukla", "affiliation": { "@type": "Organization", "name": "Department of Gastroenterology, Seth Gordhandas Sunderdas Medical College and King Edward Memorial Hospital, Mumbai, 400012, India." } }, { "@type": "Person", "name": "Joseph J Alukal", "url": "https://questionsmedicales.fr/author/Joseph%20J%20Alukal", "affiliation": { "@type": "Organization", "name": "Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA." } }, { "@type": "Person", "name": "Talan Zhang", "url": "https://questionsmedicales.fr/author/Talan%20Zhang", "affiliation": { "@type": "Organization", "name": "Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA." } }, { "@type": "Person", "name": "Paul J Thuluvath", "url": "https://questionsmedicales.fr/author/Paul%20J%20Thuluvath", "affiliation": { "@type": "Organization", "name": "Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore, MD, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Comparison of Plasma Levels of MicroRNA-155-5p, MicroRNA-210-3p, and MicroRNA-16-5p in Rheumatoid Arthritis Patients with Healthy Controls in a Case-control Study.", "datePublished": "2023-09-03", "url": "https://questionsmedicales.fr/article/37767678", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.18502/ijaai.v22i4.13608" } }, { "@type": "ScholarlyArticle", "name": "Effect of electroacupuncture on haemodynamic changes during intubation for general anaesthesia is mediated by nitric oxide synthase‑3 via the regulation of microRNA‑155, microRNA‑335 and microRNA‑383.", "datePublished": "2023-03-03", "url": "https://questionsmedicales.fr/article/36866732", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3892/mmr.2023.12970" } }, { "@type": "ScholarlyArticle", "name": "The diagnostic utility of microRNA 222-3p, microRNA 21-5p, and microRNA 122-5p for HCV-related hepatocellular carcinoma and its relation to direct-acting antiviral therapy.", "datePublished": "2022-05-21", "url": "https://questionsmedicales.fr/article/35606305", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ajg.2022.04.001" } }, { "@type": "ScholarlyArticle", "name": "MicroRNA-125a-3p, -4530, and -92a as a Potential Circulating MicroRNA Panel for Noninvasive Pancreatic Cancer Diagnosis.", "datePublished": "2022-10-08", "url": "https://questionsmedicales.fr/article/36254252", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1155/2022/8040419" } }, { "@type": "ScholarlyArticle", "name": "Development of 5-FU-modified tumor suppressor microRNAs as a platform for novel microRNA-based cancer therapeutics.", "datePublished": "2022-08-06", "url": "https://questionsmedicales.fr/article/35933584", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ymthe.2022.07.015" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies cardiovasculaires", "item": "https://questionsmedicales.fr/mesh/D002318" }, { "@type": "ListItem", "position": 3, "name": "Maladies vasculaires", "item": "https://questionsmedicales.fr/mesh/D014652" }, { "@type": "ListItem", "position": 4, "name": "Embolie et thrombose", "item": "https://questionsmedicales.fr/mesh/D016769" }, { "@type": "ListItem", "position": 5, "name": "Thrombose", "item": "https://questionsmedicales.fr/mesh/D013927" }, { "@type": "ListItem", "position": 6, "name": "Thrombose veineuse", "item": "https://questionsmedicales.fr/mesh/D020246" }, { "@type": "ListItem", "position": 7, "name": "Syndrome de Budd-Chiari", "item": "https://questionsmedicales.fr/mesh/D006502" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Syndrome de Budd-Chiari - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Syndrome de Budd-Chiari", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-15", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Syndrome de Budd-Chiari", "description": "Comment diagnostiquer le syndrome de Budd-Chiari ?\nQuels tests sanguins sont utiles ?\nQuels signes cliniques indiquent ce syndrome ?\nL'échographie Doppler est-elle utile ?\nQuand envisager une biopsie hépatique ?", "url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=MicroRNAs&page=6#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Syndrome de Budd-Chiari", "description": "Quels sont les symptômes courants ?\nLa douleur abdominale est-elle fréquente ?\nQu'est-ce que l'ascite ?\nLa jaunisse est-elle un symptôme ?\nPeut-on avoir des symptômes asymptomatiques ?", "url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=MicroRNAs&page=6#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Syndrome de Budd-Chiari", "description": "Comment prévenir le syndrome de Budd-Chiari ?\nLes anticoagulants peuvent-ils prévenir ce syndrome ?\nQuelles habitudes de vie adopter ?\nLes vaccinations sont-elles importantes ?\nFaut-il surveiller les maladies hépatiques ?", "url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=MicroRNAs&page=6#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Syndrome de Budd-Chiari", "description": "Quels traitements sont disponibles ?\nQuand utiliser des anticoagulants ?\nQu'est-ce qu'une procédure endovasculaire ?\nQuand envisager une transplantation hépatique ?\nY a-t-il des traitements symptomatiques ?", "url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=MicroRNAs&page=6#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Syndrome de Budd-Chiari", "description": "Quelles sont les complications possibles ?\nL'insuffisance hépatique est-elle fréquente ?\nQu'est-ce que l'hypertension portale ?\nPeut-on avoir des complications à long terme ?\nLes complications peuvent-elles être évitées ?", "url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=MicroRNAs&page=6#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Syndrome de Budd-Chiari", "description": "Quels sont les principaux facteurs de risque ?\nL'obésité augmente-t-elle le risque ?\nLes maladies hépatiques sont-elles un risque ?\nLes contraceptifs oraux sont-ils un facteur ?\nLe tabagisme influence-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D006502?mesh_terms=MicroRNAs&page=6#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer le syndrome de Budd-Chiari ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'échographie, l'IRM et des tests sanguins pour évaluer la fonction hépatique." } }, { "@type": "Question", "name": "Quels tests sanguins sont utiles ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests incluent les marqueurs de la fonction hépatique et les tests de coagulation." } }, { "@type": "Question", "name": "Quels signes cliniques indiquent ce syndrome ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent l'ascite, la douleur abdominale et l'hypertrophie du foie." } }, { "@type": "Question", "name": "L'échographie Doppler est-elle utile ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle permet d'évaluer le flux sanguin dans les veines hépatiques et de détecter des obstructions." } }, { "@type": "Question", "name": "Quand envisager une biopsie hépatique ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Une biopsie peut être envisagée si le diagnostic est incertain ou pour évaluer des lésions hépatiques." } }, { "@type": "Question", "name": "Quels sont les symptômes courants ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent fatigue, douleur abdominale, jaunisse et ascite." } }, { "@type": "Question", "name": "La douleur abdominale est-elle fréquente ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la douleur abdominale est un symptôme fréquent, souvent localisée dans la partie supérieure droite." } }, { "@type": "Question", "name": "Qu'est-ce que l'ascite ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "L'ascite est l'accumulation de liquide dans la cavité abdominale, souvent causée par une hypertension portale." } }, { "@type": "Question", "name": "La jaunisse est-elle un symptôme ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la jaunisse, due à une accumulation de bilirubine, est un symptôme courant du syndrome." } }, { "@type": "Question", "name": "Peut-on avoir des symptômes asymptomatiques ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains patients peuvent être asymptomatiques, surtout dans les formes chroniques." } }, { "@type": "Question", "name": "Comment prévenir le syndrome de Budd-Chiari ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention inclut la gestion des facteurs de risque comme les troubles de la coagulation et l'obésité." } }, { "@type": "Question", "name": "Les anticoagulants peuvent-ils prévenir ce syndrome ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les anticoagulants peuvent prévenir les thromboses chez les patients à risque." } }, { "@type": "Question", "name": "Quelles habitudes de vie adopter ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Adopter une alimentation équilibrée, faire de l'exercice et éviter le tabac sont bénéfiques." } }, { "@type": "Question", "name": "Les vaccinations sont-elles importantes ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, se faire vacciner contre l'hépatite peut réduire le risque de complications hépatiques." } }, { "@type": "Question", "name": "Faut-il surveiller les maladies hépatiques ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, surveiller les maladies hépatiques et les troubles de la coagulation est crucial pour la prévention." } }, { "@type": "Question", "name": "Quels traitements sont disponibles ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent des anticoagulants, des procédures endovasculaires et, dans certains cas, une transplantation hépatique." } }, { "@type": "Question", "name": "Quand utiliser des anticoagulants ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Les anticoagulants sont utilisés pour traiter les thromboses veineuses hépatiques et prévenir les complications." } }, { "@type": "Question", "name": "Qu'est-ce qu'une procédure endovasculaire ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "C'est une intervention pour débloquer les veines hépatiques, souvent par angioplastie ou stenting." } }, { "@type": "Question", "name": "Quand envisager une transplantation hépatique ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "La transplantation est envisagée en cas d'insuffisance hépatique sévère ou de complications irréversibles." } }, { "@type": "Question", "name": "Y a-t-il des traitements symptomatiques ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des traitements symptomatiques comme les diurétiques peuvent aider à gérer l'ascite." } }, { "@type": "Question", "name": "Quelles sont les complications possibles ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent l'insuffisance hépatique, la thrombose et l'hypertension portale." } }, { "@type": "Question", "name": "L'insuffisance hépatique est-elle fréquente ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'insuffisance hépatique est une complication grave pouvant survenir dans ce syndrome." } }, { "@type": "Question", "name": "Qu'est-ce que l'hypertension portale ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'hypertension portale est une augmentation de la pression dans la veine porte, causée par l'obstruction." } }, { "@type": "Question", "name": "Peut-on avoir des complications à long terme ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des complications à long terme comme la cirrhose peuvent se développer si non traitées." } }, { "@type": "Question", "name": "Les complications peuvent-elles être évitées ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être évitées par un traitement précoce et une surveillance régulière." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent les troubles de la coagulation, l'obésité, et certaines maladies hépatiques." } }, { "@type": "Question", "name": "L'obésité augmente-t-elle le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'obésité est un facteur de risque connu pour le syndrome de Budd-Chiari." } }, { "@type": "Question", "name": "Les maladies hépatiques sont-elles un risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certaines maladies hépatiques, comme la cirrhose, augmentent le risque de ce syndrome." } }, { "@type": "Question", "name": "Les contraceptifs oraux sont-ils un facteur ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'utilisation prolongée de contraceptifs oraux peut augmenter le risque de thrombose." } }, { "@type": "Question", "name": "Le tabagisme influence-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut contribuer à des problèmes vasculaires, augmentant le risque de thrombose." } } ] } ] }

Sources (10000 au total)

Comparison of Plasma Levels of MicroRNA-155-5p, MicroRNA-210-3p, and MicroRNA-16-5p in Rheumatoid Arthritis Patients with Healthy Controls in a Case-control Study.

Rheumatoid arthritis is a chronic autoimmune disease that causes inflammation and destruction of the joints. The objective of the current study was to evaluate the expression of microRNA (miR)-155-5p,...

Effect of electroacupuncture on haemodynamic changes during intubation for general anaesthesia is mediated by nitric oxide synthase‑3 via the regulation of microRNA‑155, microRNA‑335 and microRNA‑383.

Intubation for general anaesthesia is a life‑threatening risk because it can cause haemodynamic changes. Electroacupuncture (EA) has been reported to alleviate the risk of intubation. In the present s...

The diagnostic utility of microRNA 222-3p, microRNA 21-5p, and microRNA 122-5p for HCV-related hepatocellular carcinoma and its relation to direct-acting antiviral therapy.

Recent reports have emphasized the increased risk of hepatocellular carcinoma (HCC) post direct-acting antiviral (DAAs) therapy in chronic hepatitis C virus (HCV) patients. Unfortunately, reliable dia... Qiagen specific microRNA assays were utilized to assess the expression levels of the chosen microRNAs in the serum samples collected from 3 groups: (1) 50 patients with HCV-related HCC, (2) 50 patient... The mean serum values of microRNA 21-5p and microRNA 122-5p were significantly lower in the HCC post DAA therapy group than in both the group with HCC without prior exposure to DAAs (P < 0.001) and co... This is the first study to introduce microRNA 21-5p, microRNA 122-5p and microRNA 222-3p as noninvasive biomarker candidates for HCC post DAA therapy. Their altered expression among treatment-naive HC...

MicroRNA-340 and MicroRNA-450b-5p: Plasma Biomarkers for Detection of Non-Small-Cell Lung Cancer.

Since the inefficient cancer management is caused by inaccurate diagnoses, there is a need for minimally invasive method to improve the diagnostic accuracy of non-small-cell lung (NSCLC). This study i... A GSE64591 dataset included 200 samples (100 early-stage NSCLC patients and 100 noncancer control) aimed to identify a panel of circulating miRNAs in plasma. The levels of miR-340 and miR-450b-5p in p... miR-450b-5p and miR-340 in plasma was significant difference between early-stage NSCLC patients and noncancer control by searching the GSE64591 dataset. When compared with the healthy controls, the pl... The plasma levels of miR-340 combined with miR-450b-5p potentially define core biomarker signatures for improving the accuracy of NSCLC diagnosis. Moreover, circulating miR-340 and miR-450b-5p are ind...

MicroRNA 200a as a histologically independent marker for meningioma recurrence: Results of a four microRNA panel analysis in meningiomas.

Meningiomas are mostly benign neoplasms of the central nervous system. Nevertheless there are recurrences in about 20% after surgical resection. Previous studies could reveal several predictors of men... By real-time polymerase chain reaction the expressions of microRNA 21-3p, 34a-3p, 200a-3p, and 409-3p were analyzed in solid tumor and in blood samples of 51 meningioma patients as well as in blood sa... MicroRNA 200a showed significantly lower expressions in recurrent meningiomas than in newly diagnosed ones. MicroRNA 409 in meningiomas was correlated significantly with tumor volume and showed a sign... We detected microRNA 200a as a new biomarker to indicate meningioma recurrences. Future transferability to blood could be important for patient follow-up....